OTCMKTS:SPHDF

Santhera Pharmaceuticals (SPHDF) Stock Forecast, Price & News

$0.68

-9.61 (-93.39%)

(As of 08/8/2023 ET)

Compare

Today's Range: $0.68
▼
$0.68
50-Day Range: $0.68
▼
$10.29
52-Week Range: $0.68
▼
$1.20

Volume: N/A
Average Volume: 3,788 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Headlines Short Interest

About Santhera Pharmaceuticals (OTCMKTS:SPHDF) Stock

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

SPHDF Price History

30 days | 90 days | 365 days | Advanced Chart

SPHDF Stock News Headlines

July 31, 2023 | benzinga.com

Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group

July 31, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Santhera Pharmaceuticals Holding (SPHDD)

August 10, 2023 | Stansberry Research (Ad)

A 73-Year-Old Market Signal With 95% Accuracy Just Flashed

This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.

June 29, 2023 | finanznachrichten.de

Santhera Pharmaceuticals Holding AG: Santhera Publishes Timeline of the Reverse Share Split

June 29, 2023 | finance.yahoo.com

Santhera Publishes Timeline of the Reverse Share Split

June 27, 2023 | finanznachrichten.de

Santhera Pharmaceuticals Holding AG: Shareholders Approve all Board Proposals at Today's Annual General Meeting

June 27, 2023 | finance.yahoo.com

Shareholders Approve all Board Proposals at Today’s Annual General Meeting

June 21, 2023 | msn.com

Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera

August 10, 2023 | Stansberry Research (Ad)

A 73-Year-Old Market Signal With 95% Accuracy Just Flashed

This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.

June 20, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

June 20, 2023 | markets.businessinsider.com

Santhera Grants North America License For Vamorolone To Catalyst Pharma

June 20, 2023 | finance.yahoo.com

Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties

June 6, 2023 | finance.yahoo.com

Santhera Publishes Agenda for its Annual General Meeting

June 2, 2023 | seekingalpha.com

Santhera Pharmaceuticals GAAP EPS of -CHF1.17

June 1, 2023 | finanznachrichten.de

Santhera Pharmaceuticals Holding AG: Santhera Publishes Annual Report 2022

May 31, 2023 | finance.yahoo.com

Santhera Publishes Annual Report 2022

May 24, 2023 | thestreet.com

Santhera -- A Duchenne Drug With Positive Study Results That Few Know About

May 13, 2023 | thestreet.com

Santhera Drug Wins European Approval for Rare Blindness Disease

April 27, 2023 | finance.yahoo.com

Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update

April 25, 2023 | finanznachrichten.de

Santhera Pharmaceuticals Holding AG: Vamorolone NDA mid-cycle review meeting by FDA completed

April 25, 2023 | finance.yahoo.com

Vamorolone NDA mid-cycle review meeting by FDA completed

April 1, 2023 | finance.yahoo.com

Santhera Pharmaceuticals Holding AG (VTX:SANN) Is Expected To Breakeven In The Near Future

March 30, 2023 | barrons.com

Santhera Pharmaceuticals Holding AG

March 2, 2023 | finance.yahoo.com

Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy

February 8, 2023 | finance.yahoo.com

Santhera Concludes Agreement with French Authorities on Raxone® Reimbursement and Plans to Submit a Request for an Early Access Program for Vamorolone

January 10, 2023 | finanznachrichten.de

Santhera Pharmaceuticals Holding AG: Santhera enters into CHF 5 million share exchange agreement

January 10, 2023 | finance.yahoo.com

Santhera enters into CHF 5 million share exchange agreement

See More Headlines

Receive SPHDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Santhera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:SPHDF
CUSIP: N/A
CIK: N/A
Web: www.santhera.com
Phone: (161) 906-8950
Fax: N/A
Employees: 45
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Thomas Meier Ph.D. (Age 61)
Founder & Chairman
Comp: $93.48k

Mr. Dario Eklund (Age 55)
Chief Exec. Officer
Comp: $909.5k

Mr. Andrew P. Smith CGMA (Age 60)
FCMA, Chief Financial Officer

Mr. Oliver Strub (Age 60)
Exec. VP, Gen. Counsel & Sec.

Mr. Günther Metz Ph.D. (Age 65)
Head of Bus. Devel. & Exec. VP

Mr. Shabir Hasham M.D.
Chief Medical Officer

Ms. Stephanie Brown B.Sc. (Age 62)
M.B.A., Pres of North America

Mr. Marc Schrader
Head of Technical Devel. & Operations

Ms. Eva Kalias
Head of Investor Relations & Communications

Mr. Neville Kodkani M.D.
Head of Global Marketing & Partner Management

Key Competitors

View All Competitors

SPHDF Stock - Frequently Asked Questions

How have SPHDF shares performed in 2023?: Santhera Pharmaceuticals' stock was trading at $14.10 at the start of the year. Since then, SPHDF stock has decreased by 95.2% and is now trading at $0.68.
View the best growth stocks for 2023 here.
Are investors shorting Santhera Pharmaceuticals?: Santhera Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 1,143,400 shares, an increase of 254.3% from the June 15th total of 322,700 shares. Based on an average daily trading volume, of 3,200 shares, the short-interest ratio is presently 357.3 days.
View Santhera Pharmaceuticals' Short Interest.
When did Santhera Pharmaceuticals' stock split?: Shares of Santhera Pharmaceuticals reverse split before market open on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Santhera Pharmaceuticals' stock symbol?: Santhera Pharmaceuticals trades on the OTCMKTS under the ticker symbol "SPHDF."
How do I buy shares of Santhera Pharmaceuticals?: Shares of SPHDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Santhera Pharmaceuticals' stock price today?: One share of SPHDF stock can currently be purchased for approximately $0.68.
How can I contact Santhera Pharmaceuticals?: Santhera Pharmaceuticals' mailing address is Hohenrainstrasse 24, Pratteln, Basel-Landschaft (Basle. The official website for the company is www.santhera.com. The company can be reached via phone at (161) 906-8950.

This page (OTCMKTS:SPHDF) was last updated on 8/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial